Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 49

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 49
---
 on the achievement of certain annual corporate and individual performance goals. Our STI program directly aligns the interests of our executive officers and shareholders by providing an incentive for the achievement of key corporate and individual performance objectives that are critical to the success of our Company and linking a significant portion of each executive’s annual compensation to the achievement of such objectives.

Under the 2024 STI program, each named executive officer had a target incentive percentage that was a percentage of their base salary.

| Name                   |     | Percentage of Base Salary |     |
| Rick Pauls             |     |                           | 50% |
| Lorianne Masuoka, M.D. |     |                           | 40% |
| Scott Kellen           |     |                           | 40% |

2024 STI payouts were based primarily on corporate objectives, which had a 75% weighting, and to a lesser extent, individual objectives, which had a 25% weighting. The corporate objectives related to our ReMEDy2 trial, manufacturing, and raising additional capital, and were determined by the Compensation Committee to have been achieved at 76.4% of target. The individual objectives varied by executive and related to our ReMEDy2 trial, manufacturing, developing people and organization, evidence development for our product candidate DM199, accounting and financial reporting, and partnering activities. The individual objectives were determined by the Compensation Committee to have been achieved at 100% of target for our CEO, 40% of target for our CMO and 80% of target for our CFO.

The following sets forth each executive’s target bonus opportunity and actual STI payout for 2024:

| Officer Name and Position |     | 2024 Base 
 Salary    |         |     | Target Incentive 
 Percentage of    
 Base Salary      |    |   |     | Target Bonus   
 Opportunity(1) |         |     | 2024 Actual 
 Payout(1)   |         |
|:--------------------------|:----|:----------|--------:|:----|:-----------------|---:|:--|:----|:---------------|--------:|:----|:------------|--------:|
| Rick Pauls                |     | $         | 600,000 |     |                  | 50 | % |     | $              | 300,000 |     | $           | 306,975 |
| Lorianne Masuoka, M.D.    |     |           | 425,000 |